Search research articles
Contact Us
Filters
Showing results (171-180 of 280) with videos related to
Page
of 28
Sort By:
Haematologica
|
July 20, 2023
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia
Rabia Shahswar, Gernot Beutel, Razif Gabdoulline, et al.
British Journal of Haematology
|
November 5, 2019
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia
Rabia Shahswar, Gernot Beutel, Piroska Klement, et al.
Annals of Hematology
|
September 6, 2025
Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practice
Felicitas Schulz, Carolin Kellersmann, Beate Betz, et al.
Blood
|
December 17, 2013
Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications
Felicitas Thol, Robin Bollin, Marten Gehlhaar, et al.
Haematologica
|
May 28, 2021
Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with <i>nucleophosmin1</i>-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
Katrin Teich, Julia Krzykalla, Silke Kapp-Schwoerer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 28, 2017
Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice
Malte Kölling, Tamas Kaucsar, Celina Schauerte, et al.
Annals of Hematology
|
April 11, 2012
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes
Felicitas Thol, Haiyang Yun, Ann-Kathrin Sonntag, et al.
Plos One
|
November 18, 2014
Cell fate decisions in malignant hematopoiesis: leukemia phenotype is determined by distinct functional domains of the MN1 oncogene
Courteney K Lai, Yeonsook Moon, Florian Kuchenbauer, et al.
American Journal of Hematology
|
September 6, 2023
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel
Farhad Ravandi, Jacqueline Cloos, Francesco Buccisano, et al.
Journal of Hematology & Oncology
|
August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
Jonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.
Page
of 28
Search research articles
Search
Showing results (171-180 of 280) with videos related to
Sort By:
Page
of 28
Haematologica
|
July 20, 2023
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia
Rabia Shahswar, Gernot Beutel, Razif Gabdoulline, et al.
British Journal of Haematology
|
November 5, 2019
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia
Rabia Shahswar, Gernot Beutel, Piroska Klement, et al.
Annals of Hematology
|
September 6, 2025
Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practice
Felicitas Schulz, Carolin Kellersmann, Beate Betz, et al.
Blood
|
December 17, 2013
Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications
Felicitas Thol, Robin Bollin, Marten Gehlhaar, et al.
Haematologica
|
May 28, 2021
Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with <i>nucleophosmin1</i>-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
Katrin Teich, Julia Krzykalla, Silke Kapp-Schwoerer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 28, 2017
Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice
Malte Kölling, Tamas Kaucsar, Celina Schauerte, et al.
Annals of Hematology
|
April 11, 2012
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes
Felicitas Thol, Haiyang Yun, Ann-Kathrin Sonntag, et al.
Plos One
|
November 18, 2014
Cell fate decisions in malignant hematopoiesis: leukemia phenotype is determined by distinct functional domains of the MN1 oncogene
Courteney K Lai, Yeonsook Moon, Florian Kuchenbauer, et al.
American Journal of Hematology
|
September 6, 2023
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel
Farhad Ravandi, Jacqueline Cloos, Francesco Buccisano, et al.
Journal of Hematology & Oncology
|
August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
Jonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.
Page
of 28